Dr. Nishana Paul is an emerging oncologist with a strong academic foundation in radiation oncology and medical oncology. She is skilled in advanced radiation therapy planning, chemotherapy, and immunotherapies. With a special focus on gynaecological cancers and breast cancer, she ensures personalised, multidisciplinary cancer care. She has actively contributed to cancer epidemiology, registries, and multiple research studies. Fluent in English, Hindi, and Bengali, Dr. Paul is known for her precision in tumour targeting and compassionate patient-centric care.

Educational Qualifications:

• MBBS
• MD (Radiation Oncology)
• DNB (Radiation Oncology)

Professional Experience:

• Currently working as Junior Consultant, Medical Oncology at Manipal Hospitals, Rangapani.
• Over 5 years of oncology practice combining radiation therapy, chemotherapy, and immunotherapy.
• Active researcher in gynaecological and breast cancers with special emphasis on patient quality of life.

Professional Memberships:

• Association of Radiation Oncologists of India (LM-3064)
• Indian Society of Oncology (NP-205)

Publications:

• Morphine use in domiciliary care under supervision of palliative cancer clinic – AROI West Bengal Chapter Conference, 2018.
• Evaluation and comparison of treatment period duration in carcinoma cervix cases – YROC 2019, Siliguri.
• Response evaluation in carcinoma breast treated with two different regimens – AROI WB State Conference, 2019.
• Impact of anticancer treatment on quality of life with special emphasis on psychosexual behaviour in carcinoma cervix patients – AROICON 2019, Ahmedabad.
• Comparative study of transdermal buprenorphine and oral morphine in malignant pain management – Indian Journal of Palliative Care (2018).
• Association of pulmonary tuberculosis with carcinoma lung: An epidemiological study – Clinical Cancer Investigation Journal (2018).
• Teratocarcinoma of maxillary antrum: A rare presentation – Clinical Cancer Investigation Journal (2018).
• Impact of anticancer treatment on quality of life in survivors of cervical and breast cancer – Ongoing prospective study (2017–2020).